Viruses, Vol. 15, Pages 490: HIV Drug Resistance in Adults Initiating or Reinitiating Antiretroviral Therapy in Uruguay & mdash;Results of a Nationally Representative Survey, 2018 & ndash;2019

Viruses, Vol. 15, Pages 490: HIV Drug Resistance in Adults Initiating or Reinitiating Antiretroviral Therapy in Uruguay—Results of a Nationally Representative Survey, 2018–2019 Viruses doi: 10.3390/v15020490 Authors: Rosa Flieller Susana Cabrera Dora Ruchansky Amalia Girón-Callejas María Brasesco Daniel Pérez Héctor Chiparelli Claudia García-Morales Daniela Tapia-Trejo Jessica Monreal-Flores Giovanni Ravasi Michael R. Jordan Santiago Ávila-Ríos The first nationally representative cross-sectional HIV drug resistance (HIVDR) survey was conducted in Uruguay in 2018–2019 among adults diagnosed with HIV and initiating or reinitiating antiretroviral therapy (ART). Protease, reverse transcriptase, and integrase genes of HIV-1 were sequenced. A total of 206 participants were enrolled in the survey; 63.2% were men, 85.7% were >25 years of age, and 35.6% reported previous exposure to antiretroviral (ARV) drugs. The prevalence of HIVDR to efavirenz or nevirapine was significantly higher (OR: 1.82, p < 0.001) in adults with previous ARV drug exposure (20.3%, 95% CI: 18.7–22.0%) compared to adults without previous ARV drug exposure (12.3%, 11.0–13.8%). HIVDR to any nucleoside reverse transcriptase inhibitors was 10.3% (9.4–11.2%). HIVDR to ritonavir-boosted protease inhibitors was 1.5% (1.1–2.1%); resistance to ritonavir-boosted darunavir w...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research